The BAMM2 (BRAF Autophagy MEK inhibition in Melanoma) Study: A Randomized Double Blind Phase II Study of Dabrafenib and Trametinib with or without Hydroxychloroquine in Advanced BRAFV600E/K Melanoma with elevated LDH

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Advanced Melanoma
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Patient must have locally advanced unresectable stage IIIC to stage IV melanoma.
    2. Patient must have BRAFV600E or BRAFV600K tumor genotype based on a CLIA approved assay.
    3. Patient must have serum LDH > Upper limit of normal per institution standards.
    4. Patient must have an ECOG performance status of 0 or 1.

You may not be eligible for this study if the following are true:

    1. Patients who are known to be experiencing an objective partial response to immunotherapy at the time of study enrollment.
    2. History of interstitial lung disease (ILD) or chronic pneumonitis.
    3. Previously documented retinal vein occlusion.
    4. History or evidence of increased cardiovascular risk.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.